<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01221584</url>
  </required_header>
  <id_info>
    <org_study_id>NIS-CRU-DUM-2010/1</org_study_id>
    <nct_id>NCT01221584</nct_id>
  </id_info>
  <brief_title>Centralized Pan-Russian Survey on the Undertreatment of Hypercholesterolemia</brief_title>
  <acronym>CEPHEUS</acronym>
  <official_title>Centralized Pan-Russian Survey on the Undertreatment of Hypercholesterolemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to establish the proportion of patients on lipid-lowering
      pharmacological treatment reaching the LDL-C goals according to the All-Russian Scientific
      Cardiology Society guidelines/ the 4th Joint European Task Force guidelines.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Establish the proportion of patients on lipid-lowering pharmacological treatment reaching the LDL-C goals according to the All-Russian Scientific Cardiology Society guidelines/the Fourth Joint European Task Force guidelines</measure>
    <time_frame>1 visit - 1-3 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Establish the proportion of patients on lipid-lowering treatment reaching the LDL-C goals according to the Russian guidelines in the following sub-populations: Primary/secondary prevention patients, Patients with metabolic syndrome</measure>
    <time_frame>1 visit - 1-3 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Establish the proportion of patients on lipid-lowering treatment reaching the LDL-C goals according to the FJETF/ NCEP ATP III guidelines, in all population and in Primary/secondary prevention patients, Patients with metabolic syndrome</measure>
    <time_frame>1 visit - 1-3 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Establish the proportion of patients on lipid-lowering treatment reaching the non HDL-C goals according to the NCEP ATP III / updated 2004 NCEP ATP III guidelines in the sub-population patients with fasting triglycerides &gt;200 mg/dL (2.26mmol/L)</measure>
    <time_frame>1 visit - 1-3 days</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">1000</enrollment>
  <condition>Dyslipidaemia</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <description>Subject 18 years of age or older on lipid lowering drug treatment for at least 3 months, with no dose change for a minimum of 6 weeks..</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Subject on lipid lowering drug treatment for at least 3 months, with no dose change for a
        minimum of 6 weeks..
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject must be 18 years of age or older of either gender or race.

          -  Subject must provide informed consent and comply with the survey procedures.

          -  Subject is on lipid lowering drug treatment for at least 3 months, with no dose change
             for a minimum of 6 weeks.

        Exclusion Criteria:

          -  Subjects who are unwilling or unable to provide informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexey Stepanov, Prof</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Prof. Boytsov</last_name>
    <role>Principal Investigator</role>
    <affiliation>RKNPK</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Acad Oganov</last_name>
    <role>Principal Investigator</role>
    <affiliation>Center of preventive medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Krasnodar</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nizhniy Novgorod</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Novosibirsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saint-Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Samara</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Voronezh</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Yaroslavl</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>February 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 14, 2010</study_first_submitted>
  <study_first_submitted_qc>October 14, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 15, 2010</study_first_posted>
  <last_update_submitted>February 29, 2012</last_update_submitted>
  <last_update_submitted_qc>February 29, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 1, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dyslipidaemia</keyword>
  <keyword>LDL-C goals</keyword>
  <keyword>guidelines</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

